Guardant Health has an expanding pipeline that could significantly boost its future market potential. Check out my ...

Key contributors included strong clinical revenue and double-digit growth in Guardant360 test volumes. Management emphasized major milestones for Guardant360, including its transition to the Smart ...

Guardant Health showed strong revenue growth but reported increasing net losses in its second quarter earnings release.

It is recognized for its cutting-edge liquid biopsy technology used in a range of products such as Guardant360, GuardantOMNI, and Shield tests for early cancer detection. The company focuses on ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

The increase in precision oncology revenue was also attributable to an increase in reimbursement for our tests, due to an increase in Medicare reimbursement for our Guardant360 LDT test to $5,000 ...